Our contribution to UK healthcare

£2.4 billion – that’s equivalent to an extra 96,000 nurses taking care of patients

Or, with £2.4 billion the NHS could employ another 83,000 1^st year junior doctors

Or, an additional 38,000 GPs could be employed by the NHS with the £2.4 billion saved through prescribing and dispensing Teva’s generic medicines.

Collaborative working and joint working projects are specific types of partnership between the NHS and the pharmaceutical industry, which aim to improve the efficiency and delivery of patient care at a local level.

Teva’s collaborative and joint working projects put patient care right at their centre. Through the projects we combine skills, experience and / or resources from the NHS and industry to jointly develop and implement the initiative. Collaborative working really illustrates the way that Teva is able to be flexible and look at the needs of a particular patient population.

We have undertaken a number of collaborative and joint working initiatives with the NHS, along with a number of partnership working projects with NHS partners across the country.

They focussed on working with the NHS in a transparent and open manner, supporting and implementing developments in healthcare delivery for the benefit of patients, primarily in migraine and respiratory care.

If you would like to learn more about our partnerships, please contact us.

Teva Runcorn employs around 500 people, working in a variety of highly skilled roles, ranging from quality assurance, manufacturing operations, research and development, engineering, microbiology and packaging.

The site develops a range of sterile liquid products mainly for use in the treatment of respiratory conditions, and also for conditions such as migraine or multiple sclerosis, for markets all around the world.

When asked by the NHS if we could help with COVID testing, we assembled a project team and rapidly worked to repurpose sodium chloride saline solution - originally used in an inhaler device - to help with mass testing. Speed and flexibility were key when a small team from Teva’s manufacturing facility in Runcorn worked through the night to find a solution.

They came up with a way of safely and effectively repurposing this medicine in a way that quickly enabled it to be used as part of the testing process.

Developed in collaboration with patients, Life Effects™ offers information, insight and inspiration for people living with one or more chronic conditions.

It looks at how health and illness affects the lives of patients, and those around them, in a profound way that goes much further than the biology of illness and treatment.

Navigating the challenges and joys of caregiving: We also recognise the vital role of caregivers. Caregivers go to amazing lengths, embracing the challenges and demands of their changing role to bring care and joyous moments to a loved one as their health changes.

Within Life Effects™ we include advice on how to support a loved one with their ongoing health challenges, we also feature personal stories from caregivers that others may find reassuring and supportive.

With such a broad spectrum of therapy areas covered by our medicines range, we also have links with a number of charities and patient organisations. We understand the values and role these important organisations play in supporting not only patients, but also their relatives and caregivers.

Through our volunteering policy, we actively encourage colleagues to volunteer for causes close to their hearts.

A thriving life sciences industry in the UK means continued evolution and improvements in medicines, therapies and patient care.

We work with government to help them understand the work we do, the challenges we face and how the right policies and legislation can all work to improve the experiences patients have of their health and care here in the UK.

We’re proud of our UK-wide footprint across the UK, with our state of the art distribution centre and head office located in Castleford, alongside our cutting-edge R&D and manufacturing facilities in Runcorn, Cheshire and Larne, Northern Ireland, supported by regulatory and commercial teams based in Harlow.

We’re passionate about delivering highly skilled roles and job opportunities to communities across the country.

Getting a new medicine into the hands of patients can take a while. It’s a complex and expensive process.  At Teva we’re looking at new innovations such as ‘value-added medicines’, speciality generics and fixed dose combination products to meet the ever-evolving healthcare needs of the UK.

Take a deeper look at the development timeline for a medicine. On average, only one of every 10,000 promising substances will successfully pass testing in the R&D phase to be eventually approved as a marketable product. That means each molecule has a 0.1% chance of success! 02

We’re also investing in biopharmaceuticals as part of our long term strategy for the future, and to help patients both in the UK and around the world. We’re focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biopharmaceuticals (also known as biologics) are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalised treatment.